|Description||BIBF 1202 is the major in-vivo metabolite of BIBF 1120, which is an oral triple angiokinase inhibitor targeting VEGFR, PDGFR, FGFR. It is a related compound of Intedanib, which is an indolinone derivative that inhibits angiokinase and an antitumor agent. It is a novel treatment modality in oncology through blockade of the vascular endothelial growth factor (VEGF) signaling pathway thus inhibition of tumor angiogenesis.|
|B0084-474893||50 mg||$458||In stock|
|Synonyms||BIBF-1202;(3Z)-2,3-Dihydro-3-[[[4-[methyl[(4-methyl-1-piperazinyl)acetyl]amino]phenyl]amino]phenylmethylene]-2-oxo-1H-indole-6-carboxylic acid;(Z)-3-(((4-(N-methyl-2-(4-methylpiperazin-1 -yl)acetamido)phenyl)amino)(phenyl)methylene)-2-oxoindoline-6-carboxylic acid;Nintedanib Impurity 5|
|Solubility||DMSO: ≥ 45 mg/mL|
|Application||BIBF 1202 is a novel treatment modality in oncology through blockade of the vascular endothelial growth factor (VEGF) signaling pathway thus inhibition of tumor angiogenesis.|
|Quality Standard||In-house standard|
|Shelf Life||2 month in rt, long time|
|Quantity||Grams to Kilograms|
|Boiling Point||759.5±60.0 °C | Condition: Press: 760 Torr|
|Density||1.331±0.06 g/cm3 | Condition: Temp: 20 °C Press: 760 Torr|
DMH4 is a selective VEGFR-2 inhibitor (IC50 values are 161, 3558, 8038 and > 30000 nM for VEGFR-2, BMPR-I, AMPK and TGFβR-I, respectively) with antiangiogenic a...
Fruquintinib, also known as HMPL-013, is an orally available, small molecule inhibitor of vascular endothelial growth factor receptors (VEGFRs), with potential ...
TAK-593 is an oral formulation containing a small-molecule receptor tyrosine kinase inhibitor of both vascular endothelial growth factor receptor (VEGFR) and pl...
SAR131675 dose dependently inhibits the proliferation of primary human lymphatic cells, induced by the VEGFR-3 ligands VEGFC and VEGFD, with an IC50 of about 20...
BIBF 1120 esylate
Nintedanib esylate is a potent triple angiokinase inhibitor for VEGFR1/2/3, FGFR1/2/3 and PDGFRα/β.
Sorafenib is a multikinase inhibitor of Raf-1, B-Raf and VEGFR-2 with IC50 of 6 nM, 22 nM and 90 nM, respectively.
(E)-FeCP-oxindole is a human vascular endothelial cell growth factor receptor 2 (VEGFR-2) inhibitor (IC50 = 214 nM). (E)-FeCP-oxindole exhibits anticancer activ...
Cediranib maleate is a highly potent VEGFR(KDR) inhibitor with IC50 of <1 nM. It also inhibits Flt1/4 with IC50 of 5 nM/≤3 nM. It inhibits VEGF-stimulated proli...
SU5205 is a VEGFR2 inhibitor.
Anlotinib Dihydrochloride is a novel multi-target tyrosine kinase inhibitor with potential antineoplastic and anti-angiogenic activities, which was designed to ...
Toceranib phosphate is a kinase inhibitor with both antitumor and antiangiogenic activity through inhibition of KIT, vascular endothelial growth factor receptor...
Cabozantinib is a potent VEGFR2 inhibitor with IC50 of 0.035 nM and also inhibits c-Met, Ret, Kit, Flt-1/3/4, Tie2, and AXL with IC50 of 1.3 nM, 4 nM, 4.6 nM, 1...
Brivanib is the hydrolyzed form of Brivanib alaninate, which is a vascular endothelial growth factor receptor 2 (VEGFR2) inhibitor with potential antineoplastic...
SU14813 maleate is an oral, multitargeted tyrosine kinase inhibitor (TKI) targeting vascular endothelial growth factor receptors (VEGFR), platelet-derived growt...
OSI-930 is a selective thiophene-derived tyrosine kinase inhibitor with potential antineoplastic activity. Tyrosine kinase inhibitor OSI-930 inhibits stem cell ...
TSU-68 (SU6668; Orantinib) is a novel multiple receptor tyrosine kinase inhibitor with IC50 of 2.1 μM, 8 nM and 1.2 μM for VEGF-R1, PDGF-Rβ and FGF-R1, respecti...
Aflibercept is a recombinant fusion protein and acts as a VEGF inhibitor. Aflibercept is used for the treatment of wet macular degeneration and metastatic color...
H-Glu-Trp-OH inhibits VEGF, which may inhibit angiogenesis.
Vandetanib is an anti-cancer drug that is used for the treatment of certain tumours of thethyroid gland. It acts as a kinase inhibitor of a number of cell recep...
Tivozanib is an orally bioavailable inhibitor of vascular endothelial growth factor receptors (VEGFRs) 1, 2 and 3 with potential antiangiogenic and antineoplast...